VEA
CUE icon

Virtus ETF Advisers’s Cue Biopharma CUE Stock Holding History

Virtus ETF Advisers’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-476
Closed -$70K – 451
2022
Q1 		$70K Sell
476
-28
-6% -$5.94K 0.03% 352
2021
Q4 		$171K Sell
504
-17
-3% -$6.57K 0.06% 278
2021
Q3 		$228K Sell
521
-27
-5% -$9.42K 0.1% 234
2021
Q2 		$192K Sell
548
-187
-25% -$72.5K 0.08% 365
2021
Q1 		$269K Buy
735
+13
+2% +$5.35K 0.11% 267
2020
Q4 		$271K Buy
722
+320
+80% +$128K 0.11% 271
2020
Q3 		$182K Sell
402
-55
-12% -$31.7K 0.1% 307
2020
Q2 		$336K Buy
+457
New +$331K 0.16% 277

Other funds holding CUE

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Virtus ETF Advisers's CUE Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 476 shares — an estimated $70K sold.

Virtus ETF Advisers first reported a position in CUE in Q2 2020 and held it in 8 quarters. The position peaked at $336K in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

  • Virtus ETF Advisers reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 476 Cue Biopharma shares in Q2 2022, an estimated $70K.
  • Virtus ETF Advisers first reported a position in Cue Biopharma in Q2 2020 and held it in 8 quarters.
  • Virtus ETF Advisers's Cue Biopharma position peaked at $336K in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.